[Myocardial tolerance to arrhythmogenic exposure and pharmacological activation of K(ATP)-channels in rats]

Related Experiment Video

Updated: Oct 4, 2026

Dual-Dye Optical Mapping of Hearts from RyR2R2474S Knock-In Mice of Catecholaminergic Polymorphic Ventricular Tachycardia
09:36

Dual-Dye Optical Mapping of Hearts from RyR2R2474S Knock-In Mice of Catecholaminergic Polymorphic Ventricular Tachycardia

Published on: December 22, 2023

L N Maslov1, A V Krylatov, A Iu Lishmanov

  • 1Siberian State Medical University, Tomsk, 634050 Russia.

Eksperimental'Naia I Klinicheskaia Farmakologiia
|September 11, 2001
PubMed

Insights

The KATP channel activator BMS 180448 reduced ischemic and reperfusion arrhythmias in rats. This compound also prevented CsCl-induced arrhythmias but potentiated CaCl2-induced ones, suggesting a specific antiarrhythmic mechanism.

Area of Science:

  • Pharmacology
  • Cardiovascular Physiology
  • Molecular Biology

Context:

  • Ischemic heart disease and subsequent arrhythmias pose significant clinical challenges.
  • KATP channels play a crucial role in cardiac function and protection during ischemia.
  • Developing targeted therapies for arrhythmias is a key area of cardiovascular research.

Purpose:

  • To investigate the antiarrhythmic effects of the cardioselective KATP channel activator BMS 180448.
  • To determine the efficacy of BMS 180448 in preventing specific types of cardiac arrhythmias in a rat model.
  • To explore the potential mechanism underlying the observed antiarrhythmic activity.

Summary:

  • Intravenous administration of BMS 180448 (3 mg/kg) 15 minutes before coronary artery occlusion significantly decreased the incidence of ischemic and reperfusion arrhythmias in rats.
  • BMS 180448 also demonstrated antiarrhythmic effects when infused 2 minutes before reperfusion and prevented CsCl-induced arrhythmias.
  • However, BMS 180448 did not affect epinephrine-induced arrhythmias and potentiated CaCl2-induced arrhythmias, indicating a selective mechanism of action.

Impact:

  • BMS 180448 exhibits selective antiarrhythmic properties, potentially offering a novel therapeutic strategy for specific cardiac arrhythmias.
  • The findings provide insights into the role of KATP channels in modulating cardiac electrical stability during ischemic events.
  • Further research into the precise molecular mechanisms of BMS 180448 could lead to the development of more effective antiarrhythmic drugs.

More Related Videos

Isolation of Human Atrial Myocytes for Simultaneous Measurements of Ca2+ Transients and Membrane Currents10:53

Isolation of Human Atrial Myocytes for Simultaneous Measurements of Ca2+ Transients and Membrane Currents

Published on: July 3, 2013

Simultaneous Isolation of High Quality Cardiomyocytes, Endothelial Cells, and Fibroblasts from an Adult Rat Heart09:38

Simultaneous Isolation of High Quality Cardiomyocytes, Endothelial Cells, and Fibroblasts from an Adult Rat Heart

Published on: May 19, 2017

Related Concept Videos

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...